Digestive and Liver Disease
Volume 42, Issue 4 , Pages 253-260, April 2010

Cholangiocarcinoma: Update and future perspectives☆

  • Manuela Gatto

      Affiliations

    • Department of Clinical Medicine, Division of Gastroenterology, University of Rome “Sapienza”, Rome, Italy
    • ,
  • Maria Consiglia Bragazzi

      Affiliations

    • Department of Clinical Medicine, Division of Gastroenterology, University of Rome “Sapienza”, Rome, Italy
    • ,
  • Rossella Semeraro

      Affiliations

    • Department of Clinical Medicine, Division of Gastroenterology, University of Rome “Sapienza”, Rome, Italy
    • ,
  • Cristina Napoli

      Affiliations

    • Department of Clinical Medicine, Division of Gastroenterology, University of Rome “Sapienza”, Rome, Italy
    • ,
  • Raffaele Gentile

      Affiliations

    • Department of Clinical Medicine, Division of Gastroenterology, University of Rome “Sapienza”, Rome, Italy
    • ,
  • Alessia Torrice

      Affiliations

    • Department of Clinical Medicine, Division of Gastroenterology, University of Rome “Sapienza”, Rome, Italy
    • ,
  • Eugenio Gaudio

      Affiliations

    • Department of Anatomy, University of Rome “Sapienza”, Rome, Italy
    • ,
  • Domenico Alvaro

      Affiliations

    • Department of Clinical Medicine, Division of Gastroenterology, University of Rome “Sapienza”, Rome, Italy
    • Corresponding Author InformationCorresponding author at: Department of Clinical Medicine, Division of Gastroenterology, University of Rome “Sapienza”, Polo Pontino, R. Rossellini 51, 00137 Rome, Italy. Tel.: +39 06 49972023; fax: +39 06 4453319.

Received 18 November 2009; accepted 28 December 2009. published online 25 January 2010.

Article Outline

Abstract 

Cholangiocarcinoma is commonly considered a rare cancer. However, if we consider the hepato-biliary system a single entity, cancers of the gallbladder, intra-hepatic and extra-hepatic biliary tree altogether represent approximately 30% of the total with incidence rates close to that of hepatocellular carcinoma, which is the third most common cause of cancer-related death worldwide. In addition, cholangiocarcinoma is characterized by a very poor prognosis and virtually no response to chemotherapeutics; radical surgery, the only effective treatment, is not frequently applicable because late diagnosis. Biomarkers for screening programs and for follow-up of categories at risk are under investigation, however, currently none of the proposed markers has reached clinical application. For all these considerations, cancers of the biliary tree system should merit much more scientific attention also because a progressive increase in incidence and mortality for these cancers has been reported worldwide. This manuscript deals with the most recent advances in the epidemiology, biology and clinical presentation of cholangiocarcinoma.

Abbreviations: CCA, cholangiocarcinoma, IH-CCA, intra-hepatic cholangiocarcinoma, EH-CCA, extra-hepatic cholangiocarcinoma, PSC, primary sclerosing cholangitis

Keywords: Apoptosis, Cholangiocarcinoma, Cholangiocytes, Epidemiology, Proliferation, Risk factors

 

Back to Article Outline

1. Introduction 

Cholangiocarcinoma (CCA) is a malignant cancer arising from the neoplastic transformation of cholangiocytes, the epithelial cells lining the intra-hepatic and extra-hepatic bile ducts [1], [2]. Globally, CCA is the second most common primary hepatic malignancy [2], [3]. Several recent epidemiological studies have shown that incidence and mortality rates are increasing worldwide [3], [4], [5], [6]. From the anatomical point of view, CCA is classified as intra-hepatic (IH-CCA) or extra-hepatic (EH-CCA), the latter being further divided into proximal (peri-hilar), middle, and distal, depending on the location of the cancer within the extra-hepatic biliary system [2]. The peri-hilar cancers (Klatskin tumour) are commonly classified as indicated by the Bismuth–Corlette classification [7]. This form of CCA characteristically presents with signs of ductal and vascular obliteration. Biliary tract sepsis, liver failure and/or cachexia and malnutrition are the most important causes of death associated with these tumours. IH-CCA usually appears as a mass-forming lesion within the liver, which is mostly confused with metastatic tumour. These tumours usually progress insidiously, are difficult to diagnose, and have poor prognosis [8], [9]. Unfortunately, treatment options are discouraging. In fact, radical surgery, the only effective treatment, is applicable in a minority of patients due to the late clinical presentation and diagnosis of this tumour [9], [10], [11], [12]. Thus, to improve survival, the early detection of biliary tract cancer seems to be essential; serum and bile tumour markers, non-invasive and endoscopic-based imaging modalities, and histology and cytology have been attempted with varying success. The purpose of this review is to summarize the current literature concerning the epidemiology, risk factors, pathogenesis, diagnosis and treatment of biliary tract cancers.

Back to Article Outline

2. Epidemiology 

Primary liver cancer is the sixth most common cancer and third most common cause of cancer death worldwide. CCA is the second most common primary liver tumour after hepatocellular carcinoma [9], [12], [13]. Hepato-biliary malignancies account for 13% of the 7.6 million annual cancer-related deaths worldwide and for 3% of the 560,000 annual cancer-related deaths in the United States [14], [15], [16]. CCA accounts for 10–20% of the deaths for hepato-biliary malignancies. Given the poor prognosis of CCA, mortality and incidence rates are virtually similar. CCA incidence rates vary markedly worldwide, presumably reflecting differences in local risk factors and genetics [17]. Chile and Japan have the highest mortality rates in the world, followed by East Asia and India, while the lowest rates have been reported in Australia [16], [17]. In the United States, the incidence of CCA has been reported to be 0.95/100,000 for IH-CCA and 0.82/100,000 for EH-CCA [13], [14]. CCA prevalence in different racial and ethnic groups is heterogeneously distributed, with the highest age-adjusted prevalence in Hispanics (1.22/100,000) and the lowest in African Americans (0.17–0.5/100,000) [14], [15], [16], [17], [18].

Over the last 30 years, the estimated age-adjusted incidence rates of IH-CCA in the USA have increased by 165% [12] (from 0.32/100,000 in 1975–1979 to 0.85/100,000 in 1995–1999). The average age at presentation is the seventh decade of life with a male to female ratio of 1.5. The mortality rate and incidence of IH-CCA have parallel trends as age-adjusted mortality rate increased from 0.07 per 100,000 in 1973 to 0.69 per 100,000 in 1997 [12], [19]. On the other hand, the age-adjusted incidence of EH-CCA has decreased by 14% compared to data from two decades earlier. Currently, it is 1.2 per 100,000 in men and 0.8 per 100,000 in women. Similarly to IH-CCA, 65% of EH-CCA present in the seventh decade of life [12]. The mortality rate of EH-CCA declined from 0.6 per 100,000 in 1979 to 0.3 per 100,000 in 1998 [12]. With the exception of Denmark [20], [21], this scenario has been reported worldwide [14], [15], [16], [17], [18]. The significant increase in age-adjusted incidence of IH-CCA was confirmed even after correction for a prior misclassification of hilar CCA as IH-CCA [12], [17]. In Europe, the increase in IH-CCA mortality was higher in Western Europe than in Central or Northern Europe [19], [22], [23]. Very recently, data on the mortality and incidence trend for CCA have been reported also in Italy where a 40-fold increase in mortality for IH-CCA has been documented from 1980 to 2003 [6]. For EH-CCA, in contrast, mortality rates were stable or slightly decreasing in the last 10 years. Thus, as described in most countries, also in Italy the increased mortality for CCA mainly involves the intra-hepatic form suggesting different etiology and risk factors for IH- and EH-CCA [6].

Back to Article Outline

3. Risk factors 

A number of different risk factors have been definitively identified, but only a minority of patients presenting with CCA have known risk factors [9], [10], [11], [12] (Table 1). In Western countries, patients with primary sclerosing cholangitis (PSC) carry an increased risk of CCA [24]. The prevalence of CCA in PSC patients are 30–42%; different cohort and multicentric studies have identified that in 50% of CCA the diagnosis occurs together with the identification of PSC are detected during the first year of follow-up, with an annual incidence rate of 0.6–1.5% [24]. In 30–42% of PSC cases, CCA is often found incidentally at autopsy or in explanted livers of PSC patients submitted to transplantation.

Table 1. Risk factors for cholangiocarcinoma.
Risk factors
Primary sclerosing cholangitis (PSC)Refs. [24], [25], [26], [27], [28]

Infestation with liver flukesRefs. [29], [30], [31], [32]
Opisthorchis viverrini
Clonorchis sisensis
Schistosomiasis japonica

Toxic compoundsRefs. [33], [34], [35]

Congenital disorders
Caroli's disease
Choledocal cystRefs. [36], [37], [38]
Abnormal pancreatobiliary junctionRefs. [41], [42], [43]

HepatolithiasisRef. [39]
Viral hepatitis (HCV, HBV)Refs. [47], [48], [49], [50], [51], [52]

Lifestyle and diabetesRefs. [53], [54]
Alcohol
Obesity
Smoking

A European multicenter study [25], including 394 PSC patients from five European countries with a median follow-up of 18 years, has demonstrated that the majority of CCA cases (50%) were diagnosed within the first year after diagnosis of PSC and in 27% of the cases at intended liver transplantation. There was no correlation between incidence of CCA and the duration of PSC. In a second study conducted at the Mayo Clinic [26], 161 patients with PSC, who did not have CCA at study entry, were followed for a median of 11.5 years and 6.8% of patients developed CCA. The rate of CCA development was approximately 0.6% per year. Compared with the incidence rates of CCA in the general population, the relative risk of CCA in PSC was significantly increased [26]. Therefore, patients who present with their first diagnosis of PSC should be carefully screened and regularly followed-up for CCA development mainly during the first 2 years after PSC diagnosis [27], [28]. Unfortunately, no follow-up strategy for patients at risk has been yet validated. Recently, an algorithm based on CA 19-9 serum levels (cut-off value of 20U/mL) combined with abdominal US at 12-month intervals was proposed as a useful strategy for the screening/surveillance of CCA in PSC [28]. In PSC patients [24], [25], [26], [27], older age at PSC diagnosis, history of colorectal dysplasia or carcinoma, smoking, and current or former alcohol use (>80g/day), have all been suggested as additional risk factors for CCA development.

Infestation with liver flukes (Opisthorchis viverrini, Clonorchis sinensis and Schistosomiasis japonica) has been associated with an increased risk of CCA [29], [30], [31], [32]. In areas where Opisthorchis viverrini is endemic, the adjusted prevalence for CCA by age and gender is as high as 14% [31]. It is hypothesized that these parasites colonize the biliary system causing chronic inflammation and predisposing to malignant transformation [31].

Several toxic compounds have been suspected of causing CCA [33], [34], [35]. Thorotrast (thorium dioxide) needs a special mention because it was used as a radiological contrast in the years 1920–1950 and was found to increase the risk of CCA up to 300-fold in comparison with the general population [34], [35]. Because of its long biological half-life (400 years), the latency period of thorotrast-induced CCA ranges between 16 and 45 years [34], with the highest incidence between 20 and 30 years after exposure.

Caroli's disease, congenital choledocal cyst [36], [37], [38], intra-hepatic lithiasis [39], [40] and abnormal pancreatobiliary junction (PBM) [41] are additional risk factors for CCA. In particular, an abnormal pancreatic-bile duct junction, with a common channel length of 8–15mm, could influence the degree of pancreatic fluid regurgitation, resulting in an increased incidence of biliary tract malignancy [42]. A retrospective nationwide survey (1990–1999) of PBM in Japan revealed that 10.6% of PBM patients with bile duct dilatation were complicated by biliary tract cancer, and 33.6% of these were bile duct cancer, while 64.9% were gallbladder cancer. A prophylactic excision of the gallbladder and extra-hepatic bile duct has been proposed in these patients [42]. From a pathogenetic point of view, it has been considered that lysolecithin, formed as consequence of the mixing between pancreatic juice and bile, acts as detergent on the biliary epithelium favouring chronic inflammation [43]. This mechanism has been also considered for patients submitted to bilio-enteric surgical drainage for benign diseases, which represent another well-recognized category at risk. In contrast to this latter category, patients submitted to endoscopic sphincterotomy during endoscopic retrograde cholangio-pancreatography (ERCP) do not express increasing risk for CCA and this has been definitively demonstrated in three different studies performed in large series of patients with long follow-ups [44], [45], [46].

Among patients with CCA in the U.S.A., the prevalence of hepatitis C viral infection (HCV) was found to be four times higher than in the general population (0.8% vs. 0.2%) [47]. These results have been confirmed in Italy [48], in Taiwan [49] and in Japan [50] where HCV and viral hepatitis B (HBV) infection were detected in 23% and 11.5% of CCA compared to 6% and 5.5% of controls, respectively, with cumulative rates much greater than the general population [50]. Similar results were recently confirmed in a case–control study performed in China, where at multivariate analysis, significant risk factors associated with CCA development were hepatolithiasis (adjusted OR: 5.7; 95% CI: 1.9–16.8) and HBV infection (adjusted OR: 8.8; 95% CI: 5.9–13.1) [51]. A large epidemiological study from the United States confirmed that HCV infection is a risk factor for IH-CCA (hazard ratio 2.55; 95% CI: 1.3–4.9) but not for EH-CCA (hazard ratio 1.5; 95% CI: 0.6–1.85) [52].

Multiple case–control analyses have reported an association between CCA and alcohol use [53]. More recently, obesity, diabetes and smoking have been taken into consideration, especially for IH-CCA but further confirmations are need [53], [54].

Back to Article Outline

4. Molecular and cellular pathogenesis 

CCA results from malignant transformation of cholangiocytes, although recent attention has been given to the development of CCA from stem/progenitor cells located in the peribiliary glands and/or canal of Hering/bile ductules [55]. However, evidence for a role of resident stem cells exists, so far only for primitive hepatic cancers characterized by mixed hepatocellular carcinoma/CCA phenotypes [56], [57], that are currently classified as hepato-cholangiocarcinoma (CHC) [58]. A recent study has demonstrated the presence of progenitor cell markers in CHC like K7, K19, prominin-1, receptor for stem cell factor c-kit, octamer-4 transcription factor, and leukemia inhibitory factor, which were up-regulated while albumin gene expression was down-regulated [58]. Functional analyses of polycomb-group protein Bmi1, a molecule that is responsible for the self-renewal capability of many types of stem cells, was examined in IH-CCA [59]. The level of mRNA Bmi1 was significantly higher in 13 (81.3%) of 16 IH-CCA compared with the corresponding non-neoplastic tissues. Moreover, the Bmi1 knockdown in cell lines resulted in decreased colony formation, decreased cell proliferation, and increased cell senescence. Therefore, overexpression of polycomb-group protein Bmi1 is essential for colony formation and cell proliferation, probably by the repression of cellular senescence in IH-CCA [59].

A common and important contributor to the malignant transformation of cholangiocytes is chronic inflammation, often coupled with the injury of bile duct epithelium and obstruction of bile flow, which increase cholangiocyte turnover [60], [61]. Persistent inflammation is thought to promote carcinogenesis by causing damage in DNA mismatch repair genes/proteins, proto-oncogenes and tumour suppressor genes [62], and by creating a local environment enriched with cytokines and other growth factors capable to accelerate cell cycle and to favour accumulation of somatic mutations [63], [64].

Current evidence supports a primary role played by nitric oxyde (NO) induced by pro-inflammatory cytokines (TNF-α, IL-6, etc.) [65], [66], [67], [68]. Nitric oxide can directly, or through the formation of peroxynitrite species, lead to the deamination of guanine, formation of DNA adduct thereby promoting DNA mutations. The resultant DNA damage leads to an increased mutation rate and alteration of genes critical to cell proliferation control, thus triggering oncogenetic mutations [67], [68]. Dysregulation of the proto-oncogene k-ras [69], nuclear accumulation of p53 [70], [71], [72] and up-regulation of the related protein mdm-2 and WAF-1 have been observed in CCA [73], [74], [75]. Other inactivated suppressor genes include p16INK4a [76], [77], DPC4/Smad4 and APC [78], [79]. The majority of these genetic changes were described in IH-CCA. NO, together with different cytokines, can also inhibit cholangiocyte apoptosis by nytrosilation of caspase 9, and also, may induce proliferation thus favouring accumulation of somatic mutations.

Cytokines, such as interleukin-6 (IL-6), appear to play an important role in evasion from apoptosis, a mechanism that normally eliminates dysfunctional cells accumulating DNA damage [80], [81]. CCA cells have been shown to secrete IL-6 that in an autocrine fashion activates the pro-survival p38 mitogen activated protein kinase [82], [83]. In addition, IL-6 up-regulated the expression of myeloid cell leukemia-1 (Mcl-1), through STAT3 and AKT related signalling pathways [84], [85]. Mcl-1 is an anti-apoptotic protein of the Bcl-2 family of apoptotic proteins.

Cycloxygenase 2 (COX-2), activated by inflammatory cytokines and NO play an important role in CCA carcinogenesis through inhibition of apoptosis and growth stimulation [86], [87], [88], [89]. Additional induction of COX-2 is mediated by bile acids [90] and oxysterols. Other COX-2–inducing molecules include the tyrosine kinase ErbB-2, which is overexpressed in CCA and involved in CCA carcinogenesis and progression [91], [92]. ErbB-2 is an epidermal growth factor receptor (EGFR) homologue able to homodimerize or heterodimerize with other members of the EGF superfamily, resulting in activation of the Raf/MAPK-pathway [92], [93]. Constitutive overexpression of ErbB2 and/or ErbB1 in malignant cholangiocytes has been documented in more than 50% of IH-CCA [94], [95], [96]. Relevance of ErbB2 or ErbB1 related pathways in CCA has raised interest in the possibility that agents which selectively target these receptors, could potentially be effective in CCA therapy [97]. However, current experience with such ErbB targeted therapies produced only modest responses in patients with biliary tract cancers. Another recently proposed mechanism linking chronic inflammation with CCA development is related with activation-induced cytidine deaminase (AID), a member of the DNA/RNA editing enzyme family, implicated in human carcinogenesis via its mutagenic activity [98]. AID was found to be increased in biopsies from patients with PSC or CCA; whereas, only trace amounts of AID were detected in the normal liver.

We have demonstrated that proliferating cholangiocytes serve as a neuroendocrine compartment during chronic liver diseases, and as such, secrete and respond to a number of hormones and neuropeptides contributing to the autocrine and paracrine pathways that modulate liver inflammation and fibrosis [99]. A number of recent studies have shown that the nervous system, neuropeptides and endocrine hormones play a key role in the modulation of CCA growth [100]. Recently, it was demonstrated that CCA cells express GABA-A, -B, -C receptors and respond to GABA stimulation with growth inhibition. GABA inhibitory effect on malignant cholangiocyte proliferation was evident in vitro and also in vivo, by reducing the growth of CCA tumours injected subcutaneously in nude mice. Moreover, GABA has been shown to be able to inhibit malignant cholangiocyte migration, a peculiar characteristic of the CCA cells [101].

Very recently, a relevant role in modulating CCA growth and proliferation has been attributed to dopamine, found to be increased in CCA cell lines. These data represent the first evidence that dopamine metabolism is dysregulated in CCA and that modulation of dopamine synthesis may represent an alternative target for the development of therapeutic strategy [102].

Estrogens have also been shown to play a role in the promoting of CCA cell growth. Our group has demonstrated that IH-CCA express the receptors for both estrogen receptor subtypes alpha and beta and for insulin-like growth factor (IGF-1), indicating that estrogens and IGF-1 coordinately regulate CCA growth and apoptosis [103], [104]. In addition, it has been shown that the estrogen proliferative effect on CCA cells is also due to the stimulation of VEGF synthesis and secretion [103], [104].

In this experimental background, recent advances in molecular pathogenesis have highlighted the importance of epigenetic alterations including promoter hypermethylation and histone deacetylation in addition to genetic changes in the process of cholangiocarcinogenesis [105], [106]. Among hypermethylated genes, it was found that the CpG island hypermethylation is a suppressor of cytokine signaling 3 (SOCS3) gene promoter in CCA. IL-6-mediated signal transducers and activators of transcription 3 (STAT3) activation are aberrantly sustained in CCA cells, resulting in resistance to apoptosis [107]. This aberrant overexpression of IL-6 has recently been shown to be a consequence of the epigenetic silencing of the suppressor of cytokine signaling 3 (SOCS-3). SOCS-3 promoter methylation was observed in a subset of CCA samples as well as in a number CCA cell lines. Enforced overexpression of SOCS-3 in these cell lines effectively reduced the IL-6-mediated signal transduction cascade [107].

Non-coding RNAs have recently been recognized as gene specific regulators, and therefore, are similar in function to transcription factors [108], [109]. These RNAs can regulate every stage of gene expression, including transcription, mRNA stability and translation. A role for these RNAs in the neoplastic transformation of cells is emerging. Several research groups have provided evidence that microRNAs may act as key regulators of processes as diverse as early development, cell proliferation and cell death. In addition, recent studies suggest a possible link between microRNAs and various cancers, including CCA [108], [109].

Back to Article Outline

5. Helpful serum and bile biomarkers in CCA diagnosis 

For many years, efforts have been performed to identify biomarkers with adequate diagnostic accuracy for CCA in serum or biological fluids [110], [111], which could also be useful for population screening or for the surveillance of high-risk subjects including PSC patients [111], [112], [113]. Serum tumour markers are attractive because of the ease of obtaining samples and their relatively low cost. Therefore, they have been the objects of extensive investigation to aid CCA diagnosis, but unfortunately, none of these markers has reached adequate specificity for CCA [114], [115], [116], [117], [118] (Table 2).

Table 2. Recently proposed serum and bile biomarkers for the diagnosis of CCA.
BiomarkerSensitivity (%)Specificity (%)
Serum
CA 19-953–9250–98
CEA33–6879–100
IL-67392
Trypsinogen-2AUC=0.804
MUC5AC71.0190
CYFRA 21-174.792.2

Bile
CA 19-946–6160–70
CEA67–8433–80
IGF1100100
Pancreatic elastase/amylase ratio8289
Mcm56267

Carcinoembryonic antigen (CEA), which is mainly used for colorectal cancers, is of scarce utility, since it is increased only in approximately 30% of patients with CCA [115], [116], [117]. Carbohydrate antigen (CA 19-9) is the most widely used serum marker for CCA but it is also elevated in pancreatic cancer, gastric cancer, primary biliary cirrhosis and in smokers; in addition, it may be transiently increased during cholangitis or cholestasis. The sensitivity and specificity for detection of CCA in PSC are 79% and 98%, respectively, at a cut-off value of 129U/mL. Other investigators have documented that only a higher cut-off (>180U/mL) may achieve this degree of specificity [119]. According to Levy et al., a change from baseline of >63U/L has a sensitivity of 90% and specificity of 98% for CCA detection [120]. In patients without PSC, CA 19-9 sensitivity is 53% at a cut-off of >100U/L and its negative predictive value is 76–92% [121]. CA 19-9 can also be elevated in bacterial cholangitis and other gastrointestinal and gynecological neoplasias; patients lacking the blood type Lewis antigen (10% of individuals) do not produce this tumour marker [122], [123], [124], [125]. In general, as extensively discussed in recent reviews [115], [116], [117], [118], a high value of sensitivity and specificity has been reported for CA 19-9 in patients with CCA depending on the study population and the cut-off values, and this is also true for CCA complicating PSC. In addition, elevated CA 19-9 usually allows CCA diagnosis in advanced stages when radical treatments are not allowed. Therefore, current efforts aim to identify novel serum markers which can substitute CA 19-9, or can improve, when measured together, the diagnostic accuracy of CA 19-9. The serum levels of interleukin 6 [80], at a 25.8pg/mL cut-off, provide a diagnostic sensitivity of 73% and a specificity of 92%. Serum levels of IL-6 have been correlated with tumour burden in CCA patients, and interestingly, 1 month after treatment with photodynamic therapy, the mean IL-6 level decreased significantly. Although these findings are encouraging, serum IL-6 is also elevated in many patients with hepatocellular carcinoma, benign biliary disease and metastatic lesions [118]. Other biomarkers such as trypsinogen-2 [126], platelet–lymphocyte ratio (PLR), mucin-5AC [127], [128], soluble fragment of cytokeratin 19 (CYFRA21-1) [129] have been recently shown to help in the diagnosis of CCA with, in some cases, a prognostic value. In particular, mucin 1 (MUC1) and MUC5AC are not expressed by hepatocellular carcinoma, suggesting a possible role in the differential diagnosis. Moreover, a very recent study focus on CCA immunohistochemical staining for mucin, has evidenced MUC1 expression in CCA closely related to dedifferentiation and infiltrative growth pattern, suggesting that the expression of MUC1 might be associated with the progression of CCA [118].

As far as bile is concerned, the pancreatic elastase/amylase ratio, mucin-4, minichromosome maintenance replication protein (Mcm5) and insulin-like growth factor 1 (IGF1) have been explored with biliary IGF1 concentration to discriminate CCA from benign biliary disorders and pancreatic cancer (Table 2). Specifically, we measured IGF1 and vascular endothelial growth factor (VEGF) in bile of patients undergoing ERCP for biliary obstruction and evaluated the performance of these markers in differentiating EH-CCA from pancreatic cancer or benign biliary abnormalities [112]. The biliary IGF1 concentration was 15–20-fold higher in EH-CCA than the other two groups. In contrast, biliary VEGF concentration was similar in the three groups. In substance, this study indicated a marker (bile IGF1), which could be used, with absolute diagnostic accuracy, in patients undergoing ERCP for biliary obstruction, to differentiate EH-CCA from either pancreatic cancer or benign biliary disorders [112].

Proteomics of serum and bile are under investigation but definitive findings are currently unavailable [130], [131]. Another strategy is to evaluate the diagnostic performance of serum CA 19-9 together with imaging techniques [132], [133], [134]. To this regard, it has been demonstrated that the combination of serum CA 19-9 with either computed tomography (CT), magnetic resonance imaging (MRI), magnetic resonance colangio-pancreatography (MRCP) or ERCP show the best sensitivity (∼100%) but a low specificity (∼40%) in diagnosing CCA occurring in PSC patients. In contrast, the combination of serum CA 19-9 and ultrasonography (US) had intermediate specificity (62%) with a good sensitivity (91%) for detecting CCA. On the basis of test properties, cost and availability, combination of serum CA 19-9 (cut-off value of 20U/mL) and abdominal US at 12-month intervals was recently proposed as useful strategy for the screening/surveillance of CCA in PSC [28].

Back to Article Outline

6. Staging 

Understanding the patterns of spread of CCA is essential for staging and treatment planning. CCA can spread along biliary ducts, invade perineural and vascular tissues, infiltrate adjacent structures, invade lymph nodes or develop distant metastasis [135], [136], [137].

IH-CCA and EH-CCA are staged differently. A new staging system for IH-CCA was proposed by Nathan et al. [138] based on the number of tumours, vascular invasion, lymph node status and presence of metastatic disease. The presence of multiple tumours may be indicative of satellite neoplastic deposits or intra-hepatic metastatic disease from hematogenous or lymphatic spread; similarly to vascular and lymph node invasion, it is associated with poor survival. For EH-CCA, the goal of staging is to determine the local extent of the disease, as it predicts resectability and the extent of the resection. The American Joint Committee on Cancer (AJCC) staging system, also known as the TNM staging system for EH-CCA [139] is based on pathological data useful in identifying the patient prognosis but with little applicability for assessing the feasibility of surgical treatment [138]. Bismuth–Corlette classification for hilar CCA is useful for describing tumour location and its spread within the biliary tree, but it is not predictive of resectability [7]. The Memorial Sloan-Kettering Cancer Center (MSKCC) has proposed a staging system known as T-stage criteria [138]. The MSKCC staging system is based on the location and extent of ductal involvement, presence or absence of portal vein invasion, and presence or absence of hepatic lobar atrophy irrespective of metastases or lymph node status. The MSKCC staging system for hilar CCA correlates with resectability and survival, as 59% of T1 lesions are resectable with median survival of 20 months compared to 0% resectability for T3 lesions with a median survival of only 8 months [138].

Back to Article Outline

7. Treatment 

Tumour resection is the only potential cure for CCA. The median survival of patients with unresectable disease is 6–12 months [140]. All patients with resectable IH-CCA, hilar CCA, and the majority of patients with EH-CCA, require partial hepatectomy to increase the chances of negative resection margins. Preoperative evaluation includes an extensive assessment of patient fitness for major surgery, the absence of any metastatic disease and the possibility of resection margins free from cancer [141], [142], [143]. If any of these conditions are not satisfied, surgical therapy is not indicated and palliative modalities should be recommended [12], [144]. Recently, portal vein embolization (PVE) is a valuable preoperative measure when anticipating extensive liver resections with subsequent small hepatic residual volume [145]. A compensatory hypertrophy of the remnant hepatic parenchyma is induced by selectively occluding the main portal vein branch to the lobe that will be resected. This can increase the volume of the anticipated liver remnant by 12–20%, thereby reducing the rate of postoperative liver dysfunction [146], [147]. PVE is useful when the anticipated liver remnant volume is less than 20–25% of the total liver volume in patients with normal liver function, and when the anticipated liver remnant volume is 40% or less in patients with compromised liver function [147].

Transplantation is an emerging therapy for unresectable CCA without evidence of metastatic disease [148], [149]. Early experiences with liver transplantation were discouraging, given the high rates of tumour recurrence and poor patient survival. Trials with aggressive transplantation methods and adjuvant chemotherapy did not yield significantly better outcomes. Recently, stringent patient selection and neoadjuvant chemoradiation have yielded promising results with 5-year survival rates as high as 76% [148], [149]. At the Mayo Clinic, Rosen et al. [150], [151] have developed a liver transplantation protocol for HCC that provides a disease-free 5-year survival of 82%. This protocol is aimed at treating unresectable CCA in PSC patients. To be eligible for this protocol, the diagnosis of CCA needs to be confirmed histologically, CCA has to be considered unresectable with no evidence of metastatic disease. Eligible patients receive neoadjuvant chemoradiation therapy followed by staging laparotomy to rule out metastatic disease followed by living-related or cadaveric liver transplantation [151]. Currently, the use of liver transplantation for the treatment of CCA is reserved only for highly selected patients in specialized centres.

For the majority of CCA patients who are not candidates for surgical resection or transplantation, recent proposals deal with the use of photodynamic therapy (PDT) based on the intravenous administration of photosensitizing agents that preferentially accumulate in malignant cells [152], [153], [154]. In these studies, in fact, PDT alone or plus stenting improved cholestasis and quality of life considerably, and had a favourable side-effect profile. In light of these findings, recent review articles recommended PDT for patients with non-resectable disease [154]. The role of PDT adjuvant treatment before or after surgical resection needs to be assessed. It is important to bear in mind that PDT requires careful patient management. Radiotherapy (external, intraluminal, brachitherapy) received recent attention and positive findings have been reported by different centres for peri-hilar-CCA [153], [154].

As far as pharmacological therapy is concerned, CCA is characterized by a remarkable resistance to common chemotherapy. Several drugs have been tested alone in unresectable CCA and in restricted phase II studies (5-fluorouracil, methansulfon-m-anisidide, cisplatin, rifampicin, mitomycin C, paclitaxel, gemcitabine) with partial response rates of 0–9% and an average survival of 2–12 months. Certainly, 5-fluorouracil was the most commonly used drug but with the same disappointing results as the other drugs used in monotherapy [155]. Recently, the Italian Health Care System approved the use of gemcitabine. In 2005, a review [156] analysed over 13 single arm phase II studies suggesting the role of gemcitabine as an alternative to supportive care. However, randomized controlled trials are necessary to defina any real and potential increase in survival determined by this drug which shows a low toxicity. Regard to combination therapies, one of the most used therapeutic strategies is ECF (epirubicin+cisplatin+5-fluorouracil) but with disappointing results [157]. Several phase Ib and II studies evaluated the addition to gemcitabine [158] of cetuximab [159], [160], oxaliplatin/cisplatin [161], [162], [163], erlotinib [164] or capecitabine [165]. Among these studies, the effect seems to be more consistent with the combination of capecitabine and addition of oxaliplatin/cisplatin. With regard to biological therapy, ongoing pilot studies are investigating the use of sorafenib, lapatinib or bevacizumab in the treatment of unresectable CCA. Very recently, it was demonstrated that sorafenib displayed significant tumour suppression resulting in a survival benefit for treated animals that mimic human disease. In this in vivo model, sorafenib also decreased tumour Tyr (705) STAT3 phosphorylation and increased tumour cell apoptosis [166].

Studies of cellular and molecular biology have clearly demonstrated, in a high percentage of CCA, the activation of signalling pathways such as PI3-kinase and MEK/ERK, multiple receptor pathways (epidermal growth factor EGF, IGF1, estrogen receptors, VEGF) and COX2/PgE2. On the basis of this evidence, there is a rationale for pilot studies testing biological drugs acting on these targets. With regard to adjuvant chemotherapy, paucity of data makes it impossible to use that therapy after surgical resection [167]. In particular, chemotherapy with 5-fluorouracil and mitomycin C failed to improve the survival of patients undergoing surgical resection, as recently observed in a phase III study [168].

Benefits of adjuvant radiotherapy after surgical resection have been recently reviewed [167]. Overall, there are retrospective data, which, altogether, show a benefit especially with regard to dose-scaling radiation [165]. However, the only prospective study [168] denies a real benefit of radiotherapy after surgical resection of peri-hilar CCA in terms of survival. Further prospective studies are needed to reach a definitive conclusion. Although data are scarce, there are some studies [167] demonstrating a slight but significant improvement in survival for distal common bile duct cancers undergoing surgical resection and adjuvant radio-chemotherapy [169].

Back to Article Outline

Conflict of interest statement 

The authors have nothing to disclose in connection with the content of this article.

Back to Article Outline

References 

  1. Blechacz B, Gores GJ. Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology. 2008;48:308–321
  2. Welzel TM, McGlynn KA, Hsing AW, et al. Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States. J Natl Cancer Inst. 2006;98:873–875
  3. Ustundag Y, Bayraktar Y. Cholangiocarcinoma: a compact review of the literature. World J Gastroenterol. 2008;14:6458–6466
  4. Mosconi S, Beretta GD, Labianca R, et al. Cholangiocarcinoma. Crit Rev Oncol Hematol. 2009;69:259–270
  5. Khan SA, Thomas HC, Davidson BR, et al. Cholangiocarcinoma. Lancet. 2005;366:1303–1314
  6. Il Colangiocarcinoma. commissione aisf 2009; www.webaisf.com.
  7. Bismuth H, Nakache R, Diamond T. Management strategies in resection for hilar cholangiocarcinoma. Ann Surg. 1992;215:31–38
  8. Khan SA, Miras A, Pelling M, et al. Cholangiocarcinoma and its management. Gut. 2007;56:1755–1756
  9. Blechacz BR, Gores GJ. Cholangiocarcinoma. Clin Liver Dis. 2008;12:131–150
  10. Yang J, Yan LN. Current status of intrahepatic cholangiocarcinoma. World J Gastroenterol. 2008;14:6289–6297
  11. Yachimski P, Pratt DS. Cholangiocarcinoma: natural history, treatment, and strategies for surveillance in high-risk patients. J Clin Gastroenterol. 2008;42:178–190
  12. Aljiffry M, Walsh MJ, Molinari M. Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990–2009. World J Gastroenterol. 2009;15:4240–4262
  13. Khan SA, Toledano MB, Taylor-Robinson SD. Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma. Int Hepato Pancreato Biliary Assoc (Oxford). 2008;10:77–82
  14. Shaib YH, Davila JA, McGlynn K, et al. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase?. J Hepatol. 2004;40:472–477
  15. McLean L, Patel T. Racial and ethnic variations in the epidemiology of intrahepatic cholangiocarcinoma in the United States. Liver Int. 2006;26:1047–1053
  16. Blendis L, Halpern Z. An increasing incidence of cholangiocarcinoma: why?. Gastroenterology. 2004;127:1008–1009
  17. Hammill CW, Wong LL. Intrahepatic cholangiocarcinoma: a malignancy of increasing importance. J Am Coll Surg. 2008;207:594–603
  18. Shaib Y, El-Serag HB. The epidemiology of cholangiocarcinoma. Semin Liver Dis. 2004;24:115–125
  19. Nuzzo G, Giuliante F, Ardito F, et al. Intrahepatic cholangiocarcinoma. Ann Surg. 2009;249:541–542
  20. Jepsen P, Vilstrup H, Tarone RE, et al. Incidence rates of intra- and extrahepatic cholangiocarcinomas in Denmark from 1978 through 2002. J Natl Cancer Inst. 2007;99:895–897
  21. Sorensen HT, Friis S, Olsen JH, et al. Risk of liver and other types of cancer in patients with cirrhosis: a nationwide cohort study in Denmark. Hepatology. 1998;28:921–925
  22. West J, Wood H, Logan RF, et al. Trends in the incidence of primary liver and biliary tract cancers in England and Wales 1971–2001. Br J Cancer. 2006;94:1751–1758
  23. Borie F, Trétarre B, Bouvier AM, et al. Primitive liver cancers: epidemiology and geographical study in France. Eur J Gastroenterol Hepatol. 2009;21:984–989
  24. Abbas G, Lindor KD. Cholangiocarcinoma in primary sclerosing cholangitis. J Gastrointest Cancer. 2009;40:19–25
  25. Boberg KM, Bergquist A, Mitchell S, et al. Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation. Scand J Gastroenterol. 2002;37:1205–1211
  26. Burak K, Angulo P, Pasha TM, et al. Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol. 2004;99:523–526
  27. Lazaridis KN, Gores GJ. Primary sclerosing cholangitis and cholangiocarcinoma. Semin Liver Dis. 2006;26:42–51
  28. Charatcharoenwitthaya P, Enders FB, Halling KC, et al. Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis. Hepatology. 2008;48:1106–1117
  29. Shin HR, Lee CU, Park HJ, et al. Hepatitis B and C virus, Clonorchis sinensis for the risk of liver cancer: a case–control study in Pusan, Korea. Int J Epidemiol. 1996;25:933–940
  30. Kim HG, Han J, Kim MH, et al. Prevalence of clonorchiasis in patients with gastrointestinal disease: a Korean nationwide multicenter survey. World J Gastroenterol. 2009;15:86–94
  31. Poomphakwaen K, Promthet S, Kamsa-Ard S, et al. Risk factors for cholangiocarcinoma in Khon Kaen, Thailand: a nested case–control study. Asian Pac J Cancer Prev. 2009;10:251–258
  32. Andoh H, Yasui O, Kurokawa T, et al. Cholangiocarcinoma coincident with schistosomiasis japonica. J Gastroenterol. 2004;39:64–68
  33. National Toxicology Program. NTP toxicology and carcinogenesis studies of a mixture of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (CAS No. 1746-01-6), 2,3,4,7,8-pentachlorodibenzofuran (PeCDF) (CAS No. 57117-31-4), and 3,3′,4,4′,5-pentachlorobiphenyl (PCB 126) (CAS No. 57465-28-8) in female Harlan Sprague–Dawley rats (gavage studies). Natl Toxicol Program Tech Rep Ser. 2006;1–180
  34. Sahani D, Prasad SR, Tannabe KK, et al. Thorotrast-induced cholangiocarcinoma: case report. Abdom Imaging. 2003;28:72–74
  35. Lipshutz GS, Brennan TV, Warren RS. Thorotrast-induced liver neoplasia: a collective review. J Am Coll Surg. 2002;195:713–718
  36. de Vries JS, de Vries S, Aronson DC, et al. Choledochal cysts: age of presentation, symptoms, and late complications related to Todani's classification. J Pediatr Surg. 2002;37:1568–1573
  37. Pisano G, Donlon JB, Platell C, et al. Cholangiocarcinoma in a type III choledochal cyst. Aust N Z J Surg. 1991;61:855–857
  38. Voyles CR, Smadja C, Shands WC, et al. Carcinoma in choledochal cysts. Age-related incidence. Arch Surg. 1983;118:986–988
  39. Su CH, Shyr YM, Lui WY, et al. Hepatolithiasis associated with cholangiocarcinoma. Br J Surg. 1997;84:969–973
  40. Ishiguro S, Inoue M, Kurahashi N, et al. Risk factors of biliary tract cancer in a large-scale population-based cohort study in Japan (JPHC study); with special focus on cholelithiasis, body mass index, and their effect modification. Cancer Causes Control. 2008;19:33–41
  41. Tashiro S, Imaizumi T, Ohkawa H, et al. Pancreaticobiliary maljunction: retrospective and nationwide survey in Japan. J Hepatobiliary Pancreat Surg. 2003;10:345–351
  42. Miyazaki M, Takada T, Miyakawa S, et al. Risk factors for biliary tract and ampullary carcinomas and prophylactic surgery for these factors. J Hepatobiliary Pancreat Surg. 2008;15:15–24
  43. Gwak GY, Yoon JH, Lee SH, et al. Lysophosphatidylcholine suppresses apoptotic cell death by inducing cyclooxygenase-2 expression via a Raf-1 dependent mechanism in human cholangiocytes. J Cancer Res Clin Oncol. 2006;132:771–779
  44. Costamagna G, Tringali A, Shah SK, et al. Long-term follow-up of patients after endoscopic sphincterotomy for choledocholithiasis, and risk factors for recurrence. Endoscopy. 2002;34:273–279
  45. Strömberg C, Luo J, Enochsson L, et al. Endoscopic sphincterotomy and risk of malignancy in the bile ducts, liver, and pancreas. Clin Gastroenterol Hepatol. 2008;6:1049–1053
  46. Mortensen FV, Jepsen P, Tarone RE, et al. Endoscopic sphincterotomy and long-term risk of cholangiocarcinoma: a population-based follow-up study. J Natl Cancer Inst. 2008;100:745–750
  47. Chuang SC, Vecchia CL, Boffetta P. Liver cancer: descriptive epidemiology and risk factors other than HBV and HCV infection. Cancer Lett. 2008;286:9–14
  48. Donato F, Gelatti U, Tagger A, et al. Intrahepatic cholangiocarcinoma and hepatitis C and B virus infection, alcohol intake, and hepatolithiasis: a case–control study in Italy. Cancer Causes Control. 2001;12:959–964
  49. Lee CH, Chang CJ, Lin YJ, et al. Viral hepatitis-associated intrahepatic cholangiocarcinoma shares common disease processes with hepatocellular carcinoma. Br J Cancer. 2009;100:1765–1770
  50. Kobayashi M, Ikeda K, Saitoh S, et al. Incidence of primary cholangiocellular carcinoma of the liver in japanese patients with hepatitis C virus-related cirrhosis. Cancer. 2000;88:2471–2477
  51. Zhou YM, Yin ZF, Yang JM, et al. Risk factors for intrahepatic cholangiocarcinoma: a case–control study in China. World J Gastroenterol. 2008;14:632–635
  52. El-Serag HB, Engels EA, Landgren O, et al. Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: a population-based study of U.S. veterans. Hepatology. 2009;49:116–123
  53. Wu TT, Levy M, Correa AM, et al. Biliary intraepithelial neoplasia in patients without chronic biliary disease: analysis of liver explants with alcoholic cirrhosis, hepatitis C infection, and noncirrhotic liver diseases. Cancer. 2009;115:4564–4575
  54. Ahrens W, Timmer A, Vyberg M, et al. Risk factors for extrahepatic biliary tract carcinoma in men: medical conditions and lifestyle: results from a European multicentre case–control study. Eur J Gastroenterol Hepatol. 2007;19:623–630
  55. Cardinale V, Wang Y, Carpino G, et al. Multipotent stem/progenitor cells in human extrahepatic biliary tree yield hepatocytes, bile ducts and pancreatic islets. Am Assoc Study Liver Dis. 2009;
  56. Nomoto K, Tsuneyama K, Cheng C, et al. Intrahepatic cholangiocarcinoma arising in cirrhotic liver frequently expressed p63-positive basal/stem-cell phenotype. Pathol Res Pract. 2006;202:71–76
  57. Sell S, Dunsford HA. Evidence for the stem cell origin of hepatocellular carcinoma and cholangiocarcinoma. Am J Pathol. 1989;134:1347–1363
  58. Komuta M, Spee B, Vander Borght S, et al. Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin. Hepatology. 2008;47:1544–1556
  59. Sasaki M, Yamaguchi J, Ikeda H, et al. Polycomb group protein Bmi1 is overexpressed and essential in anchorage-independent colony formation, cell proliferation and repression of cellular senescence in cholangiocarcinoma tissue and culture studies. Hum Pathol. 2009;40:1723–1730
  60. Lazaridis KN, Gores GJ. Cholangiocarcinoma. Gastroenterology. 2005;128:1655–1667
  61. Jaiswal M, LaRusso NF, Burgart LJ, et al. Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. Cancer Res. 2000;60:184–190
  62. Jaiswal M, LaRusso NF, Gores GJ. Nitric oxide in gastrointestinal epithelial cell carcinogenesis: linking inflammation to oncogenesis. Am J Physiol Gastrointest Liver Physiol. 2001;281:G626–G634
  63. Schottenfeld D, Beebe-Dimmer J. Chronic inflammation: a common and important factor in the pathogenesis of neoplasia. CA Cancer J Clin. 2006;56:69–83
  64. Wise C, Pilanthananond M, Perry BF, et al. Mechanisms of biliary carcinogenesis and growth. World J Gastroenterol. 2008;14:2986–2989
  65. Sirica AE. Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy. Hepatology. 2005;41:5–15
  66. Prawan A, Buranrat B, Kukongviriyapan U, et al. Inflammatory cytokines suppress NAD(P)H:quinone oxidoreductase-1 and induce oxidative stress in cholangiocarcinoma cells. J Cancer Res Clin Oncol. 2009;135:515–522
  67. Pinlaor S, Sripa B, Ma N, et al. Nitrative and oxidative DNA damage in intrahepatic cholangiocarcinoma patients in relation to tumor invasion. World J Gastroenterol. 2005;11:4644–4649
  68. Mon NN, Kokuryo T, Hamaguchi M. Inflammation and tumor progression: a lesson from TNF-alpha-dependent FAK signaling in cholangiocarcinoma. Methods Mol Biol. 2009;512:279–293
  69. Boberg KM, Schrumpf E, Bergquist A, et al. Cholangiocarcinoma in primary sclerosing cholangitis: K-ras mutations and Tp53 dysfunction are implicated in the neoplastic development. J Hepatol. 2000;32:374–380
  70. Furubo S, Harada K, Shimonishi T, et al. Protein expression and genetic alterations of p53 and ras in intrahepatic cholangiocarcinoma. Histopathology. 1999;35:230–240
  71. Watanabe M, Asaka M, Tanaka J, et al. Point mutation of K-ras gene codon 12 in biliary tract tumors. Gastroenterology. 1994;107:1147–1153
  72. Tada M, Omata M, Ohto M. High incidence of ras gene mutation in intrahepatic cholangiocarcinoma. Cancer. 1992;69:1115–1118
  73. Ahrendt SA, Rashid A, Chow JT, et al. p53 overexpression and K-ras gene mutations in primary sclerosing cholangitis-associated biliary tract cancer. J Hepatobiliary Pancreat Surg. 2000;7:426–431
  74. Isa T, Tomita S, Nakachi A, et al. Analysis of microsatellite instability, K-ras gene mutation and p53 protein overexpression in intrahepatic cholangiocarcinoma. Hepatogastroenterology. 2002;49:604–608
  75. Levi S, Urbano-Ispizua A, Gill R, et al. Multiple K-ras codon 12 mutations in cholangiocarcinomas demonstrated with a sensitive polymerase chain reaction technique. Cancer Res. 1991;51:3497–3502
  76. Tannapfel A, Benicke M, Katalinic A, et al. Frequency of p16(INK4A) alterations and K-ras mutations in intrahepatic cholangiocarcinoma of the liver. Gut. 2000;47:721–727
  77. Kang YK, Kim WH, Lee HW, et al. Mutation of p53 and K-ras, and loss of heterozygosity of APC in intrahepatic cholangiocarcinoma. Lab Invest. 1999;79:477–483
  78. Hahn SA, Bartsch D, Schroers A, et al. Mutations of the DPC4/Smad4 gene in biliary tract carcinoma. Cancer Res. 1998;58:1124–1126
  79. Taniai M, Higuchi H, Burgart LJ, et al. p16INK4a promoter mutations are frequent in primary sclerosing cholangitis (PSC) and PSC-associated cholangiocarcinoma. Gastroenterology. 2002;123:1090–1098
  80. Goydos JS, Brumfield AM, Frezza E, et al. Marked elevation of serum interleukin-6 in patients with cholangiocarcinoma: validation of utility as a clinical marker. Ann Surg. 1998;227:398–404
  81. Yokomuro S, Tsuji H, Lunz JG, et al. Growth control of human biliary epithelial cells by interleukin 6, hepatocyte growth factor, transforming growth factor beta1, and activin A: comparison of a cholangiocarcinoma cell line with primary cultures of non-neoplastic biliary epithelial cells. Hepatology. 2000;32:26–35
  82. Park J, Tadlock L, Gores GJ, et al. Inhibition of interleukin 6-mediated mitogen-activated protein kinase activation attenuates growth of a cholangiocarcinoma cell line. Hepatology. 1999;30:1128–1133
  83. Tadlock L, Patel T. Involvement of p38 mitogen-activated protein kinase signaling in transformed growth of a cholangiocarcinoma cell line. Hepatology. 2001;33:43–51
  84. Isomoto H, Kobayashi S, Werneburg NW, et al. Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells. Hepatology. 2005;42:1329–1338
  85. Kobayashi S, Werneburg NW, Bronk SF, et al. Interleukin-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells. Gastroenterology. 2005;128:2054–2065
  86. Itatsu K, Sasaki M, Yamaguchi J, et al. Cyclooxygenase-2 is involved in the up-regulation of matrix metalloproteinase-9 in cholangiocarcinoma induced by tumor necrosis factor-alpha. Am J Pathol. 2009;174:829–841
  87. Han C, Leng J, Demetris AJ, et al. Cyclooxygenase-2 promotes human cholangiocarcinoma growth: evidence for cyclooxygenase-2-independent mechanism in celecoxib-mediated induction of p21waf1/cip1 and p27kip1 and cell cycle arrest. Cancer Res. 2004;64:1369–1376
  88. Nzeako UC, Guicciardi ME, Yoon JH, et al. COX-2 inhibits Fas-mediated apoptosis in cholangiocarcinoma cells. Hepatology. 2002;35:552–559
  89. Ishimura N, Bronk SF, Gores GJ. Inducible nitric oxide synthase upregulates cyclooxygenase-2 in mouse cholangiocytes promoting cell growth. Am J Physiol Gastrointest Liver Physiol. 2004;287:G88–G95
  90. Yoon JH, Higuchi H, Werneburg NW, et al. Bile acids induce cyclooxygenase-2 expression via the epidermal growth factor receptor in a human cholangiocarcinoma cell line. Gastroenterology. 2002;122:985–993
  91. Han C, Wu T. Cyclooxygenase-2-derived prostaglandin E2 promotes human cholangiocarcinoma cell growth and invasion through EP1 receptor-mediated activation of the epidermal growth factor receptor and Akt. J Biol Chem. 2005;280:24053–24063
  92. Sirica AE. Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinoma. World J Gastroenterol. 2008;14:7033–7058
  93. Lai GH, Zhang Z, Shen XN, et al. erbB-2/neu transformed rat cholangiocytes recapitulate key cellular and molecular features of human bile duct cancer. Gastroenterology. 2005;129:2047–2057
  94. Aishima SI, Taguchi KI, Sugimachi K, et al. c-erbB-2 and c-Met expression relates to cholangiocarcinogenesis and progression of intrahepatic cholangiocarcinoma. Histopathology. 2002;40:269–278
  95. Yoon JH, Gwak GY, Lee HS, et al. Enhanced epidermal growth factor receptor activation in human cholangiocarcinoma cells. J Hepatol. 2004;41:808–814
  96. Choi HJ, Kim HJ, Choi JH. Expression of c-erbB-2 and cyclooxygenase-2 in intrahepatic cholangiocarcinoma. Hepatogastroenterology. 2009;56:606–609
  97. Socoteanu MP, Mott F, Alpini G, et al. c-Met targeted therapy of cholangiocarcinoma. World J Gastroenterol. 2008;14:2990–2994
  98. Komori J, Marusawa H, Machimoto T, et al. Activation-induced cytidine deaminase links bile duct inflammation to human cholangiocarcinoma. Hepatology. 2008;47:888–896
  99. Alvaro D, Mancino MG, Glaser S, et al. Proliferating cholangiocytes: a neuroendocrine compartment in the diseased liver. Gastroenterology. 2007;132:415–431
  100. Marzioni M, Fava G, Benedetti A. Nervous and neuroendocrine regulation of the pathophysiology of cholestasis and of biliary carcinogenesis. World J Gastroenterol. 2006;12:3471–3480
  101. Fava G, Marucci L, Glaser S, et al. gamma-Aminobutyric acid inhibits cholangiocarcinoma growth by cyclic AMP-dependent regulation of the protein kinase A/extracellular signal-regulated kinase 1/2 pathway. Cancer Res. 2005;65:11437–11446
  102. Coufal M, Invernizzi P, Gaudio E, et al. Increased local dopamine secretion has growth promoting effects in cholangiocarcinoma. Int J Cancer. 2009;
  103. Alvaro D, Barbaro B, Franchitto A, et al. Estrogens and insulin-like growth factor 1 modulate neoplastic cell growth in human cholangiocarcinoma. Am J Pathol. 2006;169:877–888
  104. Mancino A, Mancino MG, Glaser SS, et al. Estrogens stimulate the proliferation of human cholangiocarcinoma by inducing the expression and secretion of vascular endothelial growth factor. Dig Liver Dis. 2009;41:156–163
  105. Stutes M, Tran S, DeMorrow S. Genetic and epigenetic changes associated with cholangiocarcinoma: from DNA methylation to microRNAs. World J Gastroenterol. 2007;13:6465–6469
  106. Sandhu DS, Shire AM, Roberts LR. Epigenetic DNA hypermethylation in cholangiocarcinoma: potential roles in pathogenesis, diagnosis and identification of treatment targets. Liver Int. 2008;28:12–27
  107. Isomoto H. Epigenetic alterations in cholangiocarcinoma-sustained IL-6/STAT3 signaling in cholangio-carcinoma due to SOCS3 epigenetic silencing. Digestion. 2009;79:2–8
  108. Meng F, Wehbe-Janek H, Henson R, et al. Epigenetic regulation of microRNA-370 by interleukin-6 in malignant human cholangiocytes. Oncogene. 2008;27:378–386
  109. Mott JL, Kobayashi S, Bronk SF, et al. mir-29 regulates Mcl-1 protein expression and apoptosis. Oncogene. 2007;26:6133–6140
  110. Nehls O, Gregor M, Klump B. Serum and bile markers for cholangiocarcinoma. Semin Liver Dis. 2004;24:139–154
  111. Ramage JK, Donaghy A, Farrant JM, et al. Serum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. Gastroenterology. 1995;108:865–869
  112. Alvaro D, Macarri G, Mancino MG, et al. Serum and biliary insulin-like growth factor I and vascular endothelial growth factor in determining the cause of obstructive cholestasis. Ann Intern Med. 2007;147:451–459
  113. Björnsson E, Kilander A, Olsson R. CA 19-9 and CEA are unreliable markers for cholangiocarcinoma in patients with primary sclerosing cholangitis. Liver. 1999;19:501–508
  114. Briggs CD, Neal CP, Mann CD, et al. Prognostic molecular markers in cholangiocarcinoma: a systematic review. Eur J Cancer. 2009;45:33–47
  115. Patel T, Singh P. Cholangiocarcinoma: emerging approaches to a challenging cancer. Curr Opin Gastroenterol. 2007;23:317–323
  116. Morris-Stiff G, Bhati C, Olliff S, et al. Cholangiocarcinoma complicating primary sclerosing cholangitis: a 24-year experience. Dig Surg. 2008;25:126–132
  117. Schulick RD. Primary sclerosing cholangitis: detection of cancer in strictures. J Gastrointest Surg. 2008;12:420–422
  118. Alvaro D. Serum and bile biomarkers for cholangiocarcinoma. Curr Opin Gastroenterol. 2009;25:279–284
  119. Siqueira E, Schoen RE, Silverman W, et al. Detecting cholangiocarcinoma in patients with primary sclerosing cholangitis. Gastrointest Endosc. 2002;56:40–47
  120. Levy C, Lymp J, Angulo P, et al. The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis. Dig Dis Sci. 2005;50:1734–1740
  121. Patel AH, Harnois DM, Klee GG, et al. The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am J Gastroenterol. 2000;95:204–207
  122. Narimatsu H, Iwasaki H, Nakayama F, et al. Lewis and secretor gene dosages affect CA19-9 and DU-PAN-2 serum levels in normal individuals and colorectal cancer patients. Cancer Res. 1998;58:512–518
  123. Vestergaard EM, Hein HO, Meyer H, et al. Reference values and biological variation for tumor marker CA 19-9 in serum for different Lewis and secretor genotypes and evaluation of secretor and Lewis genotyping in a Caucasian population. Clin Chem. 1999;45:54–61
  124. Akdoğan M, Saşmaz N, Kayhan B, et al. Extraordinarily elevated CA19-9 in benign conditions: a case report and review of the literature. Tumori. 2001;87:337–339
  125. Albert MB, Steinberg WM, Henry JP. Elevated serum levels of tumor marker CA19-9 in acute cholangitis. Dig Dis Sci. 1988;33:1223–1225
  126. Lempinen M, Isoniemi H, Mäkisalo H, et al. Enhanced detection of cholangiocarcinoma with serum trypsinogen-2 in patients with severe bile duct strictures. J Hepatol. 2007;47:677–683
  127. Bamrungphon W, Prempracha N, Bunchu N, et al. A new mucin antibody/enzyme-linked lectin-sandwich assay of serum MUC5AC mucin for the diagnosis of cholangiocarcinoma. Cancer Lett. 2007;247:301–308
  128. Boonla C, Sripa B, Thuwajit P, et al. MUC1 and MUC5AC mucin expression in liver fluke-associated intrahepatic cholangiocarcinoma. World J Gastroenterol. 2005;11:4939–4946
  129. Uenishi T, Yamazaki O, Tanaka H, et al. Serum cytokeratin 19 fragment (CYFRA21-1) as a prognostic factor in intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2008;15:583–589
  130. Klump B, Hsieh CJ, Dette S, et al. Promoter methylation of INK4a/ARF as detected in bile-significance for the differential diagnosis in biliary disease. Clin Cancer Res. 2003;9:1773–1778
  131. Su WC, Shiesh SC, Liu HS, et al. Expression of oncogene products HER2/Neu and Ras and fibrosis-related growth factors βFGF, TGF-beta, and PDGF in bile from biliary malignancies and inflammatory disorders. Dig Dis Sci. 2001;46:1387–1392
  132. Manfredi R, Barbaro B, Masselli G, et al. Magnetic resonance imaging of cholangiocarcinoma. Semin Liver Dis. 2004;24:155–164
  133. Abu-Hamda EM, Baron TH. Endoscopic management of cholangiocarcinoma. Semin Liver Dis. 2004;24:165–175
  134. Watanabe H, Enjoji M, Nakashima M, et al. Clinical significance of serum RCAS1 levels detected by monoclonal antibody 22-1-1 in patients with cholangiocellular carcinoma. J Hepatol. 2003;39:559–563
  135. Sakamoto E, Nimura Y, Hayakawa N, et al. The pattern of infiltration at the proximal border of hilar bile duct carcinoma: a histologic analysis of 62 resected cases. Ann Surg. 1998;227:405–411
  136. Ebata T, Watanabe H, Ajioka Y, et al. Pathological appraisal of lines of resection for bile duct carcinoma. Br J Surg. 2002;89:1260–1267
  137. Yamaguchi K, Chijiiwa K, Saiki S, et al. Carcinoma of the extrahepatic bile duct: mode of spread and its prognostic implications. Hepatogastroenterology. 1997;44:1256–1261
  138. Nathan H, Aloia TA, Vauthey JN, et al. A proposed staging system for intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2009;16:14–22
  139. Greene FL, Page DL, Fleming ID. AJCC (American Joint Committee on Cancer) cancer staging manual. 6th ed.. New York: Springer-Verlag; 2002;
  140. Kondo S, Takada T, Miyazaki M, et al. Guidelines for the management of biliary tract and ampullary carcinomas: surgical treatment. J Hepatobiliary Pancreat Surg. 2008;15:41–54
  141. Rocha FG, Matsuo K, Blumgart LH, et al. Hilar cholangiocarcinoma: the Memorial Sloan-Kettering Cancer Center experience. J Hepatobiliary Pancreat Surg. 2009;
  142. Igami T, Nishio H, Ebata T, et al. Surgical treatment of hilar cholangiocarcinoma in the “new era”: the Nagoya University experience. J Hepatobiliary Pancreat Surg. 2009;
  143. Young AL, Prasad KR, Toogood GJ, et al. Surgical treatment of hilar cholangiocarcinoma in a new era: comparison among leading Eastern and Western centers, Leeds. J Hepatobiliary Pancreat Surg. 2009;
  144. Witzigmann H, Lang H, Lauer H. Guidelines for palliative surgery of cholangiocarcinoma. Int Hepato Pancreato Biliary Assoc (Oxford). 2008;10:154–160
  145. Nagino M, Kamiya J, Nishio H, et al. Two hundred forty consecutive portal vein embolizations before extended hepatectomy for biliary cancer: surgical outcome and long-term follow-up. Ann Surg. 2006;243:364–372
  146. Abdalla EK, Barnett CC, Doherty D, et al. Extended hepatectomy in patients with hepatobiliary malignancies with and without preoperative portal vein embolization. Arch Surg. 2002;137:675–680
  147. Hemming AW, Reed AI, Howard RJ, et al. Preoperative portal vein embolization for extended hepatectomy. Ann Surg. 2003;237:686–691
  148. Singal A, Welling TH, Marrero JA. Role of liver transplantation in the treatment of cholangiocarcinoma. Expert Rev Anticancer Ther. 2009;9:491–502
  149. Schwartz JJ, Hutson WR, Gayowski TJ, et al. Liver transplantation for cholangiocarcinoma. Transplantation. 2009;88:295–298
  150. Heimbach JK, Gores GJ, Haddock MG, et al. Liver transplantation for unresectable perihilar cholangiocarcinoma. Semin Liver Dis. 2004;24:201–207
  151. Rea DJ, Heimbach JK, Rosen CB, et al. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg. 2005;242:451–458
  152. Zoepf T. Photodynamic therapy of cholangiocarcinoma. Int Hepato Pancreato Biliary Assoc (Oxford). 2008;10:161–163
  153. Baisden JM, Kahaleh M, Weiss GR, et al. Multimodality treatment with helical tomotherapy intensity modulated radiotherapy, capecitabine, and photodynamic therapy is feasible and well tolerated in patients with hilar cholangiocarcinoma. Gastrointest Cancer Res. 2008;2:219–224
  154. Kiesslich T, Wolkersdörfer G, Neureiter D, et al. Photodynamic therapy for non-resectable perihilar cholangiocarcinoma. Photochem Photobiol Sci. 2009;8:23–30
  155. Falkson G, MacIntyre JM, Moertel CG. Eastern Cooperative Oncology Group experience with chemotherapy for inoperable gallbladder and bile duct cancer. Cancer. 1984;54:965–969
  156. Dingle BH, Rumble RB, Brouwers MC. Cancer Care Ontario's Program in Evidence-Based Care's Gastrointestinal Cancer Disease Site Group. The role of gemcitabine in the treatment of cholangiocarcinoma and gallbladder cancer: a systematic review. Can J Gastroenterol. 2005;19:711–716
  157. Lee MA, Woo IS, Kang JH, et al. Epirubicin, cisplatin, and protracted infusion of 5-FU (ECF) in advanced intrahepatic cholangiocarcinoma. J Cancer Res Clin Oncol. 2004;130:346–350
  158. Yamashita Y, Taketomi A, Fukuzawa K, et al. Gemcitabine combined with 5-fluorouracil and cisplatin (GFP) in patients with advanced biliary tree cancers: a pilot study. Anticancer Res. 2006;26:771–775
  159. Paule B, Herelle MO, Rage E, et al. Cetuximab plus gemcitabine-oxaliplatin (GEMOX) in patients with refractory advanced intrahepatic cholangiocarcinomas. Oncology. 2007;72:105–110
  160. Yonemoto N, Furuse J, Okusaka T, et al. A multi-center retrospective analysis of survival benefits of chemotherapy for unresectable biliary tract cancer. Jpn J Clin Oncol. 2007;37:843–851
  161. Meyerhardt JA, Zhu AX, Stuart K, et al. Phase-II study of gemcitabine and cisplatin in patients with metastatic biliary and gallbladder cancer. Dig Dis Sci. 2008;53:564–570
  162. Charoentum C, Thongprasert S, Chewaskulyong B, et al. Experience with gemcitabine and cisplatin in the therapy of inoperable and metastatic cholangiocarcinoma. World J Gastroenterol. 2007;13:2852–2854
  163. Lee J, Kim TY, Lee MA, et al. Phase II trial of gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas. Cancer Chemother Pharmacol. 2008;61:47–52
  164. Dragovich T, Huberman M, Von Hoff DD, et al. Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial. Cancer Chemother Pharmacol. 2007;60:295–303
  165. Nehls O, Oettle H, Hartmann JT, et al. Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial. Br J Cancer. 2008;98:309–315
  166. Blechacz BR, Smoot RL, Bronk SF, et al. Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2. Hepatology. 2009;
  167. Anderson C, Kim R. Adjuvant therapy for resected extrahepatic cholangiocarcinoma: a review of the literature and future directions. Cancer Treat Rev. 2009;35:322–327
  168. Takada T, Amano H, Yasuda H, et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer. 2002;95:1685–1695
  169. Hughes MA, Frassica DA, Yeo CJ, et al. Adjuvant concurrent chemoradiation for adenocarcinoma of the distal common bile duct. Int J Radiat Oncol Biol Phys. 2007;68:178–182

☆ D. Alvaro was supported by MIUR grants: PRIN #2007, prot. 2007HPT7BA_003. E. Gaudio was supported by MIUR grants: PRIN#2007, prot. 2007HPT7BA_001 and Federate Atheneaum funds from University “Sapienza” of Rome.

PII: S1590-8658(10)00003-4

doi:10.1016/j.dld.2009.12.008

Digestive and Liver Disease
Volume 42, Issue 4 , Pages 253-260, April 2010

Article Tools